Integrated single-cell immune profiling in head and neck cancer using scRNA-seq and CyTOF
KOBRA Reports · 2025
DOI: 10.64066/kobrareports.25.0003 ↗Kurz gefasst
Fachartikel in der Zeitschrift KOBRA Reports, 2025. Verfasst von Gamin Kim und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea government.
Abstract (Originalsprache)
Head and Neck Squamous Cell Carcinoma (HNSCC) is the seventh most common cancer globally, with limited treatment options for recurrent or metastatic cases.Immune checkpoint inhibitors (ICIs), particularly PD-1 inhibitors such as Nivolumab, have emerged as promising therapies capable of restoring T-cell function and enhancing anti-tumor responses.Clinical studies have demonstrated that Nivolumab significantly improves both progression-free survival and overall survival compared to standard chemotherapy.However, the response to immunotherapy remains highly variable among patients, highlighting the need to understand the immunological mechanisms that drive such differential outcomes.In this study, we investigated the immune landscape of patients with HNSCC receiving anti-PD-1 therapy by integrating single-cell RNA sequencing (scRNA-seq) with mass cytometry (CyTOF)-based validation.Peripheral blood mononuclear cells (PBMCs) were obtained from two clinical groups: those with durable clinical benefit and those with early disease progression.PBMCs were longitudinally collected from responders and non-responders to anti-PD-1 therapy.Using scRNA-seq, we profiled transcriptional heterogeneity across immune subsets and tracked clonal expansion of T cells.Key immune cell populations associated with response status were identified and candidate markers of clinical benefit were prioritized.To further validate and quantify these findings at the protein level, we developed a customized CyTOF panel targeting immune phenotypes of interest.The panel was designed through an international harmonisation process and developed in collaboration with the Human Immune Monitoring Center (HIMC) at the Precision Immunology Institute, Icahn School of Medicine at Mount Sinai.This approach enabled us to assess treatment-induced changes across a broad range of immune cell types.Our findings provide insights into the peripheral immune correlates of anti-PD-1 response and demonstrate the value of combining transcriptomic and proteomic single-cell analyses in immunotherapy research.These results may contribute to the development of predictive biomarkers and patient stratification strategies for ICIs in HNSCC.
Förderung
- National Research Foundation of Korea
- Korea government
Zitieren
APA
Kim, G., & Kim, H. R. (2025). Integrated single-cell immune profiling in head and neck cancer using scRNA-seq and CyTOF. KOBRA Reports. https://doi.org/10.64066/kobrareports.25.0003
Vancouver
Kim G, Kim HR. Integrated single-cell immune profiling in head and neck cancer using scRNA-seq and CyTOF. KOBRA Reports. 2025. doi:10.64066/kobrareports.25.0003
BibTeX
@article{Kim2025,
author = {Kim, Gamin and Kim, Hye Ryun},
title = {Integrated single-cell immune profiling in head and neck cancer using scRNA-seq and CyTOF},
journal = {KOBRA Reports},
year = {2025},
doi = {10.64066/kobrareports.25.0003}
}
EUVIMED